Comparing two types of membranes to reduce heparin use in dialysis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the effectiveness of HYDROLINK™ and HeprAN™ membranes in minimizing the dose of peridialytic heparin during hemodialysis sessions for patients with chronic kidney disease. By reducing heparin use, the study seeks to lower the risk of bleeding complications associated with hemodialysis. Eligible participants are adults over 18 years who have been on chronic hemodialysis for at least three months. The study will employ a crossover design, allowing each patient to experience both membrane types during their treatment sessions.

Why it matters

Who can join: the full rules

inclusion criteria :

* Patients with Age \> 18 years
* Chronic hemodialysis for at least 3 months
* Hemodialysis three times a week
* On per dialytic heparin therapy (UFH or LMWH)
* Affiliated to the French Social Security
* Having given their consent for this study

exclusion criteria :

* Patients undergoing Hemodiafiltration (HDF)
* Pregnant or lactating woman
* Patient participating in another interventional study
* Persons deprived of liberty by judicial or administrative decision
* Adults under legal protection (under guardianship or curators)
* Persons under a legal protection measure
* Patients with a history of HIT
* Patients with acquired or congenital coagulation disorders
* Pathology with active neoplasia (Myeloma, Waldenström disease, solid cancers)
* Patient on an ACE inhibitor (ACE inhibitor)
* Patient requiring transfusion during the study period
* Patient not hemoglobin-stabilized (mean Hb \< 10g/dL or \>12 g/dL in the previous month)
* Patient septic or with significant inflammation (defined as C-reactive protein \> 25mg/L) at the time of inclusion
* Patient requiring per-dialytic parenteral nutrition
* Patient requiring hospitalization or scheduled surgery during the study period
* Vascular access (Arteriovenous Fistula or Arteriovenous graft with the possibility of 2 needles) not allowing a sufficient blood pump flow (\< 300 mL/min determined during the screening phase = blood flow prescribed by the nephrologist)
* Patient dialyzing on catheter ("single line" or "double line") or in unipuncture on Arteriovenous fistula on the day of the screening session
* Net ultrafiltration on the day of the screening session \> 4000 mL

Where it's running

• Chu Reims
  Reims, France Recruiting

Study contacts

• Study coordinator: Antoine BRACONNIER
• Email: abraconnier@chu-reims.fr
• Phone: 03 26 78 41 40

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD

  In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.

  Recruiting Yonsei University · Seoul · NCT07524101

• Single 3 mg Azvudine safety and blood-level test for adults with mild-to-moderate kidney decline and healthy adults

  This trial gives a single 3 mg dose of Azvudine to adults with mild-to-moderate kidney function decline and to healthy adults to test how the body handles the drug and whether it is safe.

  Recruiting Phase 1 Henan Genuine Biotech Co., Ltd. · Beijing, Beijing Municipality · NCT07001436

• Examining amino acid loss in patients undergoing kidney treatment

  This study looks at how much amino acid is lost in patients receiving kidney treatment in the ICU compared to those who aren't, to help improve nutrition for people with kidney problems.

  Recruiting Medical University of Vienna · Vienna, State of Vienna · NCT06659835

• Assessing quality of life in children with posterior urethral valves

  This study looks at how being treated for posterior urethral valves affects the quality of life for boys aged 6 to 17, focusing on their kidney health and daily living.

  Recruiting Hospices Civils de Lyon · Bron, Bron · NCT06439862

• Combining DV and Toripalimab for Kidney Preservation in Patients with Urothelial Carcinoma

  This study is testing a new combination treatment of DV and toripalimab to see if it can help people with kidney problems and bladder cancer keep their kidneys while treating their cancer.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06354231

• SelfWrap-Assisted Arteriovenous Fistulas for Chronic Kidney Disease

  This study is testing if a new wrap called SelfWrap can make it safer and more effective for people with chronic kidney disease to have a new arteriovenous fistula created.

  Recruiting at 28 sites VenoStent · Bullhead City, Arizona and 27 other locations · NCT06001827

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.